MTOR/MYCAxis regulates O-GlcNAc transferase expression and O-GlcN acylation in breast cancer

Molecular Cancer Research

Volumn 13, Issue 5, 2015, Pages 923-933

  Sodi, Valerie L ^a   Khaku, Sakina ^a   Krutilina, Raisa ^b   Schwab, Luciana P ^b   Vocadlo, David J ^c   Seagroves, Tiffany N ^b   Reginato, Mauricio J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90 ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; N ACETYLGLUCOSAMINE; O LINKED BETA N ACETYLGLUCOSAMINE; PHOSPHATIDYLINOSITOL 3 KINASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; MTOR PROTEIN, HUMAN; MYC PROTEIN, HUMAN; N ACETYLGLUCOSAMINYLTRANSFERASE; O-GLCNAC TRANSFERASE; TARGET OF RAPAMYCIN KINASE; UDP-N-ACETYLGLUCOSAMINE-PEPTIDE BETA-N-ACETYLGLUCOSAMINYLTRANSFERASE;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; METABOLIC REGULATION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; ACYLATION; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CELL PROLIFERATION; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ACYLATION; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, TRANSGENIC; N-ACETYLGLUCOSAMINYLTRANSFERASES; PROTO-ONCOGENE PROTEINS C-MYC; TOR SERINE-THREONINE KINASES; TRANSFECTION;

EID: 84942321625     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0536     Document Type: Article

References (51)

1. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008;18: 54-61.
2. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
3. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
4. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 1991;266:4706-12.
5. McClain DA. Hexosamines asmediators of nutrient sensing and regulation in diabetes. J Diabetes Complications 2002;16:72-80.
6. Hanover JA, Krause MW, Love DC. Bittersweet memories: linking metabolism to epigenetics through O-GlcNAcylation. Nat Rev Mol Cell Biol 2012;13:312-21.
7. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 2007;446:1017-22.
8. Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. Cross talk betweenOGlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem 2011;80:825-58.
9. Comer FI, HartGW.O-GlcNAc and the control of gene expression. Biochim Biophys Acta 1999;1473:161-71
10. Bond MR, Hanover JA. O-GlcNAc cycling: a link between metabolism and chronic disease. Annu Rev Nutr 2013;33:205-29.
11. Chou TY, Dang CV, Hart GW. Glycosylation of the c-Myc transactivation domain. Proc Natl Acad Sci U S A 1995;92:4417-21.
12. Shaw P, Freeman J, Bovey R, Iggo R. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 1996;12:921-30.
13. Medina L, Grove K, Haltiwanger RS. SV40 large T antigen is modified with O-linked N-acetylglucosamine but not with other forms of glycosylation. Glycobiology 1998;8:383-91.
14. Chou TY, Hart GW. O-linked N-acetylglucosamine and cancer: messages from the glycosylation of c-Myc. Adv Exp Med Biol 2001;491:413-8.
15. Hanover JA. Glycan-dependent signaling: O-linked N-acetylglucosamine. FASEB J 2001;15:1865-76.
16. Yang WH, Park SY, Nam HW, Kim do H, Kang JG, Kang ES, et al.NFkappaB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions. Proc Natl Acad Sci U S A 2008;105:17345-50.
17. Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi G, Walker S, et al. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene 2010;29:2831-42.
18. Gu Y, Mi W, Ge Y, Liu H, Fan Q, Han C, et al. GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res 2010;70:6344-51.
19. Champattanachai V, Netsirisawan P, Chaiyawat P, Phueaouan T, Charoenwattanasatien R, ChokchaichamnankitD, et al. Proteomic analysis and abrogated expression of O-GlcNAcylated proteins associated with primary breast cancer. Proteomics 2013;13:2088-99.
20. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. Critical role of O-Linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem 2012; 287:11070-81.
21. Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, et al. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer. Cancer Res 2013;73:5277-87.
22. Yi W, Clark PM, Mason DE, Keenan MC, Hill C, Goddard WA3rd, et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 2012;337:975-80.
23. Mi W, Gu Y, Han C, Liu H, Fan Q, Zhang X, et al. O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim Biophys Acta 2011;1812:514-9.
24. Zhu Q, Zhou L, Yang Z, Lai M, Xie H, Wu L, et al. O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Med Oncol 2012;29:985-93.
25. Rozanski W, Krzeslak A, Forma E, Brys M, BlewniewskiM, Wozniak P, et al. Prediction of bladder cancer based on urinary content of MGEA5 andOGT mRNA level. Clin Lab 2012;58:579-83.
26. Shi Y, Tomic J, Wen F, Shaha S, Bahlo A, Harrison R, et al. Aberrant OGlcNAcylation characterizes chronic lymphocytic leukemia. Leukemia 2010;24:1588-98.
27. Ferrer CM, Lynch TP, Sodi VL, Falcone JN, Schwab LP, Peacock DL, et al. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Mol Cell 2014; 54:820-31.
28. Krzeslak A, Forma E, Bernaciak M, Romanowicz H, Brys M. Gene expression of O-GlcNAc cycling enzymes in human breast cancers. Clin Exp Med 2012;12:61-5.
29. Yehezkel G, Cohen L, Kliger A, Manor E, Khalaila I. O-linked beta-Nacetylglucosaminylation (O-GlcNAcylation) in primary and metastatic colorectal cancer clones and effect of N-acetyl-beta-D-glucosaminidase silencing on cell phenotype and transcriptome. J Biol Chem 2012; 287:28755-69.
30. Shaw RJ, Cantley LC. Ras, PI3;K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30.
31. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes, and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
32. Schmidt EV, Ravitz MJ, Chen L, Lynch M. Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway. Cell Cycle 2009;8:1344-51.
33. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009;15:6479-83.
34. Hynes NE, Stoelzle T. Key signalling nodes in mammary gland development and cancer: Myc. Breast Cancer Res 2009;11:210.
35. Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J, et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003;5:733-40.
36. Gloster TM, Zandberg WF, Heinonen JE, Shen DL, Deng L, Vocadlo DJ. Hijacking a biosynthetic pathway yields a glycosyltransferase inhibitor within cells. Nat Chem Biol 2011;7:174-81.
37. Schwab LP, PeacockDL, MajumdarD, Ingels JF, Jensen LC, Smith KD, et al. Hypoxia-inducible factor 1alpha promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res 2012;14; R6.
38. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
39. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62.
40. Reginato MJ, Mills KR, Becker EB, Lynch DK, Bonni A, Muthuswamy SK, et al. Bim regulation of lumen formation in cultured mammary epithelial acini is targeted by oncogenes. Mol Cell Biol 2005;25:4591-601.
41. Zhang F, Snead CM, Catravas JD. Hsp90 regulates O-linked beta-N-acetylglucosamine transferase: a novel mechanism of modulation of protein O-linked beta-N-acetylglucosaminemodification in endothelial cells.AmJ Physiol Cell Physiol 2012;302:C1786-96.
42. Teng SC, Chen YY, Su YN, Chou PC, Chiang YC, Tseng SF, et al. Direct activation ofHSP90A transcription by c-Myc contributes to c-Myc-induced transformation. J Biol Chem 2004;279:14649-55.
43. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998;42:273-9.
44. Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 2003;30:709-16.
45. Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984;38:627-37.
46. Morrish F, Isern N, Sadilek M, Jeffrey M, Hockenbery DM. c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene 2009;28:2485-91.
47. Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med 2013;3:pii: a014217.
48. Dang CV. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer research 2010;70:859-62.
49. Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, et al. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 2008;68:589-96.
50. Chou TY, Hart GW, Dang CV. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem 1995;270:18961-5.
51. Overath T, Kuckelkorn U, Henklein P, Strehl B, Bonar D, Kloss A, et al. Mapping of O-GlcNAc sites of 20 S proteasome subunits and Hsp90 by a novel biotin-cystamine tag. Mol Cell Proteomics 2012;11:467-77.